Policy | March 03, 2025
PMBJP has led to a total savings of Rs. 30,000 crore for citizens: Health Minister Nadda
In financial year 2024-25, PMBJP has made sales of Rs. 1,760 crore (at MRP) till Feb 2025
In financial year 2024-25, PMBJP has made sales of Rs. 1,760 crore (at MRP) till Feb 2025
WuXi XDC's fully integrated ADC discovery service platform will significantly boost the speed and efficiency of LigaChem's ADC development programs
The safety profile of Opdualag observed in this analysis was consistent with the known profiles of nivolumab and relatlimab
Plans underway to expand screening capacity by 50% for greater accessibility
The company anticipates 2025 worldwide sales to be between $64.1 billion and $65.6 billion
These results represent critical milestones for Philogen, as Fibromun has the potential to become second product to successfully complete multinational clinical trials with registration potential
Dyrupeg will be available as 6 mg solution for injection in prefilled syringe and is intended for the reduction in the duration of neutropenia
EBITDA grew by 11% on a YoY basis to Rs. 296 crore due to improved performance in CDMO Sterile Injectables, CRDMO and Generics
Recommendation based on results of Phase 3 CheckMate -9DW clinical trial demonstrating statistically significant and clinically meaningful improvement in overall survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib in this patient population
Subscribe To Our Newsletter & Stay Updated
